Natera(NTRA)

AUSTIN, TXDiagnostics12 H-1B visas (FY2023)

Focus: Natera is a public diagnostics company headquartered in Austin, TX with 5,001-10,000 employees, operating across oncology, transplant, and reproductive health testing. The company leverages cell-free DNA and advanced molecular profiling to deliver precision diagnostic tests at scale.

Profile data last refreshed 4h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

5001-10000

Open Jobs

204+153 this month

Hot — 296 jobs added in 30d

Net +153 (296 new, 143 removed). Aggressive expansion phase.

Should You Work at Natera?

AI assessment

Natera is a high-growth diagnostics player with strong commercial momentum and emerging oncology/transplant platforms, but profitability concerns and limited pharma-style pipeline may constrain long-term stability.

Why Work Here

Strong revenue growth trajectory ($820M FY2024 → $1.1B FY2025, +34% YoY) demonstrates market traction in high-value diagnostic segments.

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.1B

Pipeline & Clinical Trials

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monit

NSCLC, Stage I, II, III

N/A

Clinical Trials (1)

NCT06854939A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

N/A

Help build intelligence for Natera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 30 programs spanning oncology (ctDNA monitoring, early detection), transplant rejection (Prospera), and reproductive health, signaling sustainable multi-year development momentum.

Commercial hiring surge (66 open roles) indicates aggressive market expansion and sales infrastructure investment, creating clear advancement pathways for field-facing roles.

Watch Out For

Persistent net losses ($-435M FY2025, $-548M FY2024) despite revenue growth suggests profitability challenges and potential pressure on R&D or headcount.
Only 5 early-stage programs (Phase 1-2) vs. 25 diagnostic/platform studies signal limited traditional drug pipeline depth and heavy reliance on test-based revenue model.

Generated by Claude from Natera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnanc

Vanishing Twin

N/A

Clinical Trials (1)

NCT05004337Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

N/A

Multiple Gestation Study

Trisomy 13

N/A

Clinical Trials (1)

NCT02278536Multiple Gestation Study

N/A

Single-gene Noninvasive Prenatal Testing

Single Gene NIPT

N/A

Clinical Trials (1)

NCT06808880EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

N/A

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cel

Microdeletion Syndromes

N/A

Clinical Trials (1)

NCT02109770Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

N/A

Natera Ovarian Cancer Detection Assay

Adnexal Mass

N/A

Clinical Trials (1)

NCT03485651Natera Ovarian Cancer Detection Assay

N/A

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

Colo-rectal Cancer

N/A

Clinical Trials (1)

NCT07046585Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

N/A

Blood draw

Chromosome 13 Aneuploidy

N/A

Clinical Trials (1)

NCT01574781Non-invasive Prenatal Diagnostic Validation Study

N/A

Natera empower comprehensive hereditary cancer panel

Hereditary Cancer Syndrome

N/A

Clinical Trials (1)

NCT07195071Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

N/A

Renasight

Kidney Diseases

N/A

Clinical Trials (1)

NCT05846113Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

N/A

MMDx

Kidney Transplant Rejection

N/A

Clinical Trials (1)

NCT04239703Trifecta-Kidney cfDNA-MMDx Study

N/A

ctDNA Assay in Patients With Resectable Pancreatic Cancer

Pancreas Cancer

N/A

Clinical Trials (1)

NCT05052671ctDNA Assay in Patients With Resectable Pancreatic Cancer

N/A

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated F

Trisomy 21

N/A

Clinical Trials (1)

NCT01852708Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

N/A

Prospera

Kidney Transplant Rejection

N/A

Clinical Trials (1)

NCT04091984The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

N/A

The Prospera™ Test

Heart Transplant Failure and Rejection

N/A

Clinical Trials (1)

NCT06414603A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

N/A

The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.

Cancer of the Rectum

N/A

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

22q11 Deletion Syndrome

N/A

Clinical Trials (1)

NCT02381457SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

N/A

Trifecta-Lung cfDNA-MMDx Study

Lung Transplantation

N/A

Clinical Trials (1)

NCT05837663Trifecta-Lung cfDNA-MMDx Study

N/A

Blood draw to measure the levels of dd-cf DNA

Cardiac Allograft Vasculopathy

N/A

Clinical Trials (1)

NCT05756088Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

N/A

SIGNATERA™ ctDNA testing

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT05379907Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

N/A

Signatera Genome ultra-sensitive ctDNA blood test

Endometrial Cancer

N/A

Clinical Trials (3)

NCT07565857Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

N/A

NCT07339384Signatera Assessment in Early-Stage Endometrial Cancer

N/A

NCT07689812A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

N/A

blood sample for Signatera

Early and Locally Advanced Breast Cancer

N/A

Clinical Trials (1)

NCT07084558ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

N/A

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Canc

Colorectal Cancer Screening

N/A

Clinical Trials (1)

NCT06620627Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

N/A

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Melanoma

N/A

Clinical Trials (1)

NCT05736523Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

N/A

BESPOKE Study of ctDNA Guided Immunotherapy

Colorectal Cancer

N/A

Clinical Trials (1)

NCT04761783BESPOKE Study of ctDNA Guided Immunotherapy

N/A

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

Breast Cancer

N/A

Clinical Trials (1)

NCT05914792Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

N/A

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Colorectal Cancer

N/A

Clinical Trials (1)

NCT04264702BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

N/A

Blood draw

Spinal Muscular Atrophy (SMA)

N/A

Clinical Trials (1)

NCT01663584Multi-disease Carrier Screening Test Validation

N/A

preimplantation diagnosis

Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)

N/A

Clinical Trials (1)

NCT01023048Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

N/A

Biopsy

Kidney Transplantation

N/A

Clinical Trials (1)

NCT06476717Donor-derived Cell-free DNA in Kidney Transplant Recipients

N/A

Sample Collection for Ongoing Research and Product Evaluation Study

Breast Cancer

N/A

Clinical Trials (3)

NCT07763197Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

N/A

NCT07750886Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

N/A

NCT07318051Sample Collection for Ongoing Research and Product Evaluation Study

N/A

ctDNA

Breast Cancer

N/A

Clinical Trials (1)

NCT05058183Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

N/A

Blood Draw

Trisomy 13

N/A

Blood draw

Pregnancy Following IVF With PGS/PGD

N/A

Clinical Trials (1)

NCT01546324Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

N/A

Whole blood for ctDNA

Germ Cell Cancer Metastatic

N/A

Clinical Trials (1)

NCT07401316Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

N/A

Prospera

Lung Transplant Rejection

N/A

Clinical Trials (2)

NCT07718633Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)

N/A

NCT05170425LAMBDA 002 (Lung Registry) Study

N/A

ctDNA-Guided Treatment Strategy

Breast Neoplasms

N/A

Clinical Trials (1)

NCT07214532Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

N/A

Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring

Biliary Tract Cancer

N/A

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Transplant Rejection

N/A

Clinical Trials (1)

NCT03984747Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

N/A

Prospera

Heart Transplant

N/A

Clinical Trials (1)

NCT05309382Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

N/A

MMDx diagnostic test

Heart Transplant Rejection

N/A

Clinical Trials (1)

NCT04707872Trifecta-Heart cfDNA-MMDx Study

N/A

Preimplantation Genetic Diagnosis

Single Gene Disorders

N/A

Clinical Trials (1)

NCT01197872Clinical Use of Parental Support To Detect Single Gene Mutations

N/A

High Risk Multiple Gestation Study

Trisomy 13

N/A

Clinical Trials (1)

NCT02278874High Risk Multiple Gestation Study

N/A

Prenatal Screening for Down Syndrome With DNAFirst

Trisomy 21

N/A

Clinical Trials (1)

NCT01966991Prenatal Screening for Down Syndrome With DNAFirst

N/A

Prospera Transplant Assessment

Heart Transplant Failure and Rejection

N/A

Clinical Trials (1)

NCT05081739Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation

N/A

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

Heart Transplant Rejection

N/A

Clinical Trials (1)

NCT05205551Prospera Test Evaluation in Cardiac Transplant (ProTECT)

N/A

Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Manage

Twin to Twin Transfusion Syndrome

N/A

Clinical Trials (1)

NCT05312814Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.

N/A

Natera KidneyScan

Transplant;Failure,Kidney

N/A

Clinical Trials (1)

NCT03765203Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients

N/A

Capecitabine

Rectal Adenocarcinoma

Phase 1

Clinical Trials (1)

NCT05108428Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Phase 1

Interview Prep Quick Facts

Portfolio: 61 clinical trials

Top TAs: Oncology, Nephrology, Rare Diseases

H-1B (2023): 12 approvals

SEC Filings: 2 available

Open Roles: 204 active jobs

Therapeutic Area Focus

31 pipeline

6 pipeline

3 pipeline

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$1.1B32%

R&D Spend

$321M(30%)1%

Net Income

-$435M

Hiring Trend

Actively Hiring

204

Open Roles

+38

Added

-32

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Natera(NTRA)

Should You Work at Natera?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (204)

Phlebotomist Test Coordinator - San Antonio, TX

Clinical Data Operator - Austin, TX

Associate QA Specialist-Temp

Senior Scientist, R&D Assay Development

Accessioning Team Runner - Pleasanton, CA

Supervisor, R&D Sample Management

Senior Product Manager, Oncology

Associate Scientist, R&D

Clinical Oncology Specialist

Clinical Field Specialist

Shipping Specialist - Pleasanton, CA

Clinical Data Operator - Pleasanton, CA

Lead Biostatistician (Oncology Clinical Studies)

Lab Waste Technician

Lab Waste Technician

Manager Clinical Lab

Supervisor, Clinical Lab

Clinical Laboratory Scientist II

Senior Automation Support Engineer

Accessioning Team Runner

Strategic Account Manager

Senior Scientist, R&D Design Transfer & Product Development

Senior Scientist, R&D Design Transfer & Product Development

Shipping Specialist 1

Equipment Associate

Financials (FY2025)

Hiring Trend

Visa Sponsorship